Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
An Open-Label, Non-Comparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Sponsor: Astellas Pharma Inc
Listed as NCT00036179, this PHASE2 trial focuses on Candidiasis and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 8 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.
This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jan 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Créteil, France , Frankfurt, Germany , Genova, Italy , Graz, Austria , Huddinge, Sweden , Kaiserslautern, Germany , Leipzig, Germany , Linz, Austria , London, United Kingdom and 11 more locations